JonesResearch downgraded Kezar Life Sciences to Hold from Buy without a price target after the company announced a strategic restructuring to focus on clinical assets. The analyst thinks it is a positive sign that Kezar is prioritizing clinical zetomipzomib programs over preclinical discovery. However, given the lack of major near term catalysts, the firm downgraded the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KZR:
